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We examined the immunohistochemical reactivity for vascular endothelial growth factor receptor 3 (VEGFR-3), a
protein playing an important role in lymphangiogenesis, in breast cancer. A retrospective series of 77 invasive ductal
breast carcinomas was investigated. The relationship between VEGFR-3 expression and clinicopathologic parameters
was examined for statistical signiﬁcance using Pearson’s chi-square ðw2Þ test and Fisher’s exact test (when no5).
Threshold for signiﬁcance was po0:05: Patient age ranged from 31 to 77 years (mean: 55 years). The VEGFR-3
immunoreactivity was as follows: 5 cases were negative (6.5%), 35+(45.4%), 27++ (35.1%), and 10+++ (13.0%).
Reactions were positive for both lymphatic and blood vessels in several cases. VEGFR-3-positive reactions were more
frequent in the tumor periphery than within the tumor. Immunoreactivity was also observed in myoepithelial cells
surrounding both normal ducts and ducts with ductal carcinoma in situ. Statistical analysis of VEGFR-3 reactions was
not signiﬁcantly related to node status, microvessel density, and tumor grade. Ploidy showed a tendency towards
signiﬁcance ðp ¼ 0:063Þ; however, owing to the limited number of cases, statistical signiﬁcance was not reached.
VEGFR-3 lacks lymphatic vessel speciﬁcity and is also expressed in blood vessels, myoepithelial cells, and neoplastic
cells.
r 2005 Elsevier GmbH. All rights reserved.
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The vascular growth factor family (VEGF-A, -B, -C, -
D, and placenta growth factor — PlGF) is involved in
angiogenesis and lymphangiogesis [30]. This has led to
the investigation of metastasis mechanisms with thee front matter r 2005 Elsevier GmbH. All rights reserved.
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ss: fschmitt@ipatimup.pt (F.C. Schmitt).purpose to block the growth of new blood vessels (BVs)
and lymphatic vessels (LVs) in order to inhibit
neoplastic dissemination [9]. However, it has been
shown that VEGF-D may have different biologic
functions in mouse and man [2]. VEGF-D is recognized
as an angiogenic promoter, mitogenic for endothelial
cells in vitro. It is expressed at different embryonic sites
and in human tumors, and also induces lymphangiogen-
esis and metastatic spread via LVs in mouse tumor
models [2].
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(VEGFR-3, Flt-4) is a tyrosine kinase receptor for
VEGF-C and VEGF-D expressed in LVs [22]. The
interaction between VEGF-C and VEGFR-3 plays an
important role in the preservation of LVs and lym-
phangiogenesis [22,33]. VEGFR-3 activity is supposed
to induce lymphangiogenesis and LV hyperplasia, but it
is also upregulated in tumor blood vessels and is
involved in neoplastic angiogenesis [11,18]. VEGFR-3
is expressed preferentially in LVs, although Patanen et
al. [21] have described its consistent expression in other
endothelial cells, such as the lining of fenestrated
capillaries in bone marrow, splenic and hepatic sinu-
soids, kidney glomeruli, adenohypophysis, thyroid
gland, parathyroid gland, adrenals, and choroids
plexus. Moreover, Valtola et al. [29] have demonstrated
VEGFR-3 expression in blood capillaries of normal and
neoplastic breast tissue.
Identiﬁcation of intra-tumoral LVs can be very
difﬁcult, even impossible with the use of the available
means. This is partly due to the mechanical stress caused
by neoplastic expansion in a conﬁned area, compressing
the newly formed channels [1].
Increased lymphatic vasculature was observed in in
situ and in invasive ductal breast carcinoma [26].
Patients with the highest relative VEGFR-3-positive
immunostaining most likely have lymph node metastasis
[17]. Intratumoral lymphangiogenesis with signiﬁ-
cantly enhanced lymph node and lung metastases was
observed in human breast cancer transplanted onto
nude mice [27]. However, an experimental tumor model
has demonstrated that lymphatic metastasis occurs in
the absence of functional intratumoral lymphatics;
the functional LVs surrounding the tumor are sufﬁcient
to allow for metastatic dissemination of malignant
cells [19].
Thus, we investigated VEGFR-3 immunoreactivity in
invasive ductal breast carcinoma to evaluate this
lymphangiogenic marker for its usefulness under routine
conditions using a commercially available antibody, and
to analyze its importance for breast cancer diagnosis
and prognostic evaluation.Materials and methods
Patients and tumor samples
Formalin-ﬁxed, parafﬁn-embedded samples obtained
from 77 invasive ductal carcinomas were retrieved from
the pathology ﬁles of the IPATIMUP, Porto, Portugal.
One of the authors reviewed all the cases classiﬁed
previously on the basis of the 1981 WHO recommenda-
tions [31] and now revised according to the most recent
WHO classiﬁcation [28]; histologic grading was per-formed using the modiﬁed criteria of Bloom and
Richardson in the light of the advances achieved in the
classiﬁcation of breast cancer, described by Elston and
Ellis [5].VEGFR-3 Immunohistochemical procedure
Immunohistochemistry was carried out with the
streptavidin-biotin-peroxidase complex technique using
a primary antibody raised against VEGFR-3 (Zymed
Laboratories Inc., CA, USA) diluted 1:200. Brieﬂy,
deparafﬁnized and rehydrated sections were immersed
in 0.01M citrate buffer (pH 6.0) and microwaved at
700w for 15min. The slides were then incubated with
3% hydrogen peroxide in methanol for 10min and in
Ultravision Block Solution (Neomarkers, Freemont,
CA, USA) for 10min at room temperature before
30min-incubation with the primary antibody. Sec-
tions were sequentially washed in PBS 1X with 0.02%
Tween 20 and incubated with biotinylated goat anti-
polyvalent antibody for 10min, streptavidin peroxidase
for 10min, and developed with 3,30-diamino-benzidine
for 10min. The slides were counterstained with Mayer’s
hematoxylin (Merck, Dermstadt, Germany). Negative
controls were carried out by omitting primary antibody;
regarding the positive controls, we used invasive ductal
breast carcinoma tissue as indicated by the manu-
facturer, leading to satisfactory immunostaining in
the LVs.Assessment of positive reactions
For immunohistochemistry, the expression of
VEGFR-3 was evaluated considering cytoplasmic stain-
ing and, eventually, nuclear staining. The slides were
analyzed by two pathologists using a double blind
method.
We semiquantitatively assessed the distribution of the
marker in endothelial and epithelial cells independently.
For this, the following grading system was used:
negative (), absence of expression; slightly positive
staining (+), expression in up to 10% of cells;
moderately positive (++), expression in over 10% up
to 50% of cells; strongly positive (+++), expres-
sion in over 50%. The positive reactions were assessed in
hot spot areas where proliferating vascular struc-
tures and epithelial malignant cells were present and
stained. The positive reactions were discriminated
according to tissue localization: peri- and intratumoral
for LVs and BVs and neoplastic cells. To clear up
disagreements, the cases were analyzed by the two
observers using a double-head microscope, and a ﬁnal
consensus was reached.
ARTICLE IN PRESS
A.L. Filho et al. / Pathology – Research and Practice 201 (2005) 93–99 95Clinical and pathologic parameters
The prognostic factors herein studied were reported
by our group previously [14]. The VEGFR-3 results
were correlated with some clinical and pathologic
parameters as follows: Histologic grade: grade I, II, or III [5]: tubule and
gland formation 475%, 10–75%, or o10%, nuclear
pleomorphism (small-regular uniform cells, moderate
increase in size and variability or marked variation),
and mitotic counts. Axillary lymph node status: negative or positive for
metastasis. Proliferative index assessed by MIB-1 immunohisto-
chemical reaction: the score was determined by two
pathologists counting at least 1000 neoplastic cells in
10–20 ﬁelds in a double blind method; cases with
p15% of positive tumor cells were considered to have
a low proliferative index, cases with415% of positive
cells were considered to have a high proliferative
index, as described previously [25]. Microvessel density: microvessel density was deter-
mined by counting vessel structures positive for factor
VIII-related antigen. If single cells or clusters of cells
clearly separated from adjacent clusters and back-
ground, with or without lumen, were positive, we
considered these an individual vessel, as recom-
mended in previous studies [14]. Areas of ﬁbrosis,
necrosis and inﬂammation, as well as vessels with a
muscle wall, were excluded from counting. Two
observers simultaneously counted the microvessels in
the three most vascularized areas in a X200 ﬁeld
(0.74mm2). As there was no statistical difference
when considering the highest count of each case or its
average count, the results were analyzed for the
average vessel count of an individual case. Ploidy: Ploidy was assessed in material obtained from
parafﬁn sections, stained by the Feulgen method, and
measured using an image analysis system (Ahrens
System, Bargteheide/Hamburg, Germany).Statistical analysis
For statistical analysis, some parameters were
grouped as follows:1. VEGFR-3
 VEGFR-3 expression: 0 and 1+ were evaluated as
negative;
 2+ and 3+ were positive.
2. Histologic grade I and histologic grade II /III.
3.Fig. 1. VEGFR-3 expression in myoepithelial cells of normal
lobules.Microvessel density (MVD) was subdivided into two
categories:p30 and430 (mean microvessels in three
ﬁelds).4. MIB immunoreactions were subdivided into two
groups of positive cells: p15% and 415%.
The relationship between VEGFR-3 expression and
clinic-pathologic parameters was examined for statisti-
cal signiﬁcance using Pearson’s chi-square ðw2Þ test and
Fisher’s exact test (when no5), the threshold for
signiﬁcance being po0:05:Results
VEGFR-3 immunostaining was observed both in LVs
and BVs in several cases. The overall VEGFR-3
reactions were as follows: ﬁve cases were negative
(6.5%), 35+(45.4%), 27++ (35.1%) and 10+++
(13.0%). VEGFR-3-positive reaction was more frequent
in the tumor periphery than within the tumor. Intratu-
moral-positive reactions were recognized in ﬁlamentous
deformed structures compressed by neoplastic masses
resembling lymphatics and by small vessels similar to
BVs.
There were different combinations of VEGFR-3-
positive reactions in LVs and BVs in the periphery of
the tumor and within. In most cases, VEGFR-3 was
concomitantly expressed by LVs and BVs in the
periphery of the tumor. There were a few cases in which
only LVs were positive for VEGFR3, and the BVs were
negative. We also observed positivity for VEGFR-3 in
myoepithelial cells surrounding normal ducts and ducts
with ductal carcinoma in situ (Figs. 1 and 2). In some
cases, VEGFR-3 was expressed in the cytoplasm of
carcinoma cells, there being no relationship with the
positivity in the respective LVs and BVs.
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Fig. 2. Positive VEGFR-3 reaction in myoepithelial cells
surrounding ducts with ductal carcinoma in situ.
Fig. 3. Intratumoral lymphatics marked for VEGFR-3 com-
pressed within neoplastic cells. Note the small BVs also
positive for VEGFR-3.
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Lymphatic vessels were stained mainly in the periph-
ery of the tumor, including adipose tissue. Intratumoral
lymphatics predominantly presented as compressed
structures faintly marked for VEGFR-3 and frequently
associated with small BVs also positive for VEGFR-3
(Fig. 3). In 55 cases (71.4%) LVs were positive; from
these cases, 22 (28.6%) were also positive for LVs within
the tumor. Immunoreactive intra-tumoral LVs were
observed in 25 cases (32.4%).Fig. 4. In the periphery of neoplastic tumor, BVs were
frequently large, and positive reactions frequently occurred
in an elastic portion of the vessels.VEGFR-3 and BVs
BVs were positive in the periphery of the tumor in 52
cases (67.5%) and within the tumor in 22 (28.6%).
Concomitant BV-positive reactions within and in the
periphery of the tumor were observed in 20 cases
(25.9%). Immunoreactive BVs within the tumor fre-
quently presented as small structures with one or two
nuclei. BVs in the periphery were frequently larger, and
VEGFR-3 staining was also observed in an elastic
portion of these vessels (Fig. 4).VEGFR-3 general reactions correlated with clinical
parameters
Dichotomized negative and positive VEGFR-3 im-
munoreactions were considered for the evaluation of
VEGFR-3 expression.
Patient age ranged from 31 to 77 years (mean: 55
years). Table 1 shows the association between prognos-
tic parameters and VEGFR-3 immunoreactivity. The
prognostic parameters were not complete for all the 77cases studied. Of these 77 cases, clinical information
about nodal status and MIB-1 was available for 69
cases; ploidy for 61; MVD for 74; and grading for 68.
Statistical analyses of the VEGFR-3 reactions were not
signiﬁcant for nodal status ðp ¼ 0:256Þ; microvessel
density (MVD) ðp ¼ 0:632Þ; and tumor grade ðp ¼
0:493Þ: Ploidy showed a tendency towards signiﬁcance
ðp ¼ 0:063Þ; however, as the diploid samples comprised
a very small series, Fisher’s exact test revealed no
signiﬁcant correlation ðp ¼ 0:115Þ; nor did MIB-1
immunoreactivity ðp ¼ 0:264Þ:
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Our results, obtained using a commercially available
VEGFR-3 antibody under routine conditions in paraf-
ﬁn-embedded samples of invasive breast ductal carcino-
ma, have revealed interesting points that might be
considered a critical approach regarding the regulation
of lymphangiogenesis in malignant tumors.
VEGFR-3 is expressed in vascular endothelium early in
development and in angiogenic endothelium, but is almost
restricted to LVs in adults. Conversely, it lacks speciﬁcity
in tumors and is upregulated in angiogenic endothelium
[4]. Furthermore, VEGFR-3 was recently demonstrated in
lymphatic and vascular precursor cells [24].
VEGFR-3 upregulation in BVs has previously been
documented in breast carcinomas, and the consistency
of this ﬁnding is well established [29]. VEGFR-3
expression in tumor blood and LVs is believed to play
an important role in mediating lymphangiogenic factor-
induced neovascularization, and is signiﬁcantly corre-
lated with VEGF-D expression, nodal status, and
prognosis [16]. In addition, VEGFR-3 expression was
also detected in cancer cells of colon-rectal adenocarci-
nomas [34], as well as in normal-hyperplastic and
malignant prostatic cells [13], myeloid leukemia cells
[6], and pancreatic endocrine malignant cells [7]. These
studies certainly corroborate in part our observations.
Surprisingly, we came upon an unexpected ﬁnding
related to the strong expression of VEGFR-3 in
myoepithelial cells. As shown in Fig. 1, the myoepithe-
lial cells were uniformly stained with anti-VEGFR-3,
outlining a subtle drawing of the cytoplasmic limits of
the cells. VEGFR-1 and -2 expressions have previously
been demonstrated in smooth muscle cells of vessel walls
in the porcine placenta and non-pregnant uterus [32],
which leads to the speculation that VEGFR-3 might
exert a similar regulation. VEGFR-3 ligands, VEGF-C,
and -D were found to be expressed in vascular smooth
muscle vessels of BVs [21]. Most recently, Rutanen et al.
[23] have corroborated the ﬁnding of VEGF-D expres-
sion in smooth muscle cells mainly in large arteries of
atherosclerotic lesions, and they have also reported that
VEGFR-2, but not VEGFR-3, is expressed in lamina
intima and lamina media of larger arteries. In addition,
VEGFR-3 was found in endothelial cells of adventitial
LVs. Curiously, cells migrating from the lateral somatic
edge into the limb buds can differentiate into three cell
populations: myocytes, blood and lymphatic endothelial
cells [8]. In vivo experiments with non-neoplastic
conditions have demonstrated that smooth muscle cells
downregulate VEGFR-3 expression, thus reducing the
required signaling capacity of developing LVs [30]. We
hypothesize that smooth muscle cells and myoepithelial
cells can upregulate VEGFR-3 in breast cancer.
Recently, Padera et al. [20] demonstrated that tumor
compression impairs intratumoral lymphatic activity,
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but not of the LVs in the tumor periphery, most likely
caused by less pressure. This complicated issue must be
carefully evaluated for the role of intra- and peritumoral
vasculature in terms of therapeutic targets and metastatic
conduit for malignant neoplastic cells [12]. The function
of lymphangiogenesis in breast cancer must be evaluated
carefully. The increasing knowledge encourages research
that aims at establishing therapeutic strategies and aid for
evaluation of prognosis [3,12]. Quantiﬁcation of lympha-
tics seems to be restricted because of the great difﬁculty in
counting intratumoral vessels. Firstly, as reported pre-
viously [20], the neoplastic pressure deforms the vessels,
making the identiﬁcation of lymphatics doubtful. Sec-
ondly, the lack of VEGFR-3 speciﬁcity does not allow for
the discrimination between small LVs and BVs, which are
presumed to occur in active angiogenic processes as in
neoplastic conditions. Finally, the assessment of vessel
quantiﬁcation has a number of different protocols, with
signiﬁcant [15] and non-signiﬁcant results achieved in
breast cancer patients [14]. The use of VEGFR-3 in
breast carcinoma has been reported previously, and, in
spite of the optimism concerning VEGFR-3 speciﬁcity
for lymphatics, the microlymphatic count had neither a
prognostic value nor did it correlate with the axillary’s
lymph node status [10].References
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